vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2021-1-30-37vtio-1312Research ArticleИСКУССТВЕННЫЕ ОРГАНЫARTIFICIAL ORGANSИмплантация модулятора сердечной сократимости при хронической сердечной недостаточности и фибрилляции предсердий, результаты 6-месячного наблюдения ста пациентовImplantation of a cardiac contractility modulator in chronic heart failure and atrial fibrillation: results of a 6-month follow-up of one hundred patientsУскачТ. М.UskachT. M.

Москва.

Moscow.

СапельниковО. В.SapelnikovO. V.

121552, Москва, 3-я Черепковская ул., д. 15а.

15а, 3rd Cherepkovskaya str., Moscow, 121552.

СафиуллинаА. А.SafiullinaA. A.

Сафиуллина Альфия Ахатовна.

121552, Москва, 3-я Черепковская ул., д. 15а.

Тел. (495) 414-66-69

Alfiya Safiullina.

15а, 3rd Cherepkovskaya str., Moscow, 121552.

Phone: (495) 414-66-69

a_safiulina@mail.ruГришинИ. Р.GrishinI. R.

121552, Москва, 3-я Черепковская ул., д. 15а.

15а, 3rd Cherepkovskaya str., Moscow, 121552.

АманатоваВ. А.AmanatovaV. A.

121552, Москва, 3-я Черепковская ул., д. 15а.

15а, 3rd Cherepkovskaya str., Moscow, 121552.

АкчуринР. С.AkchurinR. S.

121552, Москва, 3-я Черепковская ул., д. 15а.

15а, 3rd Cherepkovskaya str., Moscow, 121552.

ТерещенкоС. Н.TereshchenkoS. N.

Москва.

Moscow.

Научный медицинский исследовательский центр кардиологии Минздрава России; Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияNational Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional EducationRussian FederationНаучный медицинский исследовательский центр кардиологии» Минздрава РоссииРоссияNational Medical Research Center of CardiologyRussian Federation2021100420212313037Copyright © Ускач Т.М., Сапельников О.В., Сафиуллина А.А., Гришин И.Р., Аманатова В.А., Акчурин Р.С., Терещенко С.Н., 20212021Ускач Т.М., Сапельников О.В., Сафиуллина А.А., Гришин И.Р., Аманатова В.А., Акчурин Р.С., Терещенко С.Н.Uskach T.M., Sapelnikov O.V., Safiullina A.A., Grishin I.R., Amanatova V.A., Akchurin R.S., Tereshchenko S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1312

Цель: изучить влияние модуляции сердечной сократимости (МСС) у пациентов с хронической сердечной недостаточностью (ХСН) и фибрилляцией предсердий (ФП). Материалы и методы. В группе из 100 пациентов с ХСН и ФП до имплантации устройства МСС и через 6 месяцев наблюдения проводились следующие исследования: 12-канальная ЭКГ, трансторакальная ЭхоКГ, тест 6-минутной ходьбы, определение уровня про-натрийуретического N-концевого пептида (NT-proBNP), анкетирование по Миннесотскому опроснику качества жизни больных с ХСН (MHFLQ). Все пациенты до операции получали длительную оптимальную медикаментозную терапию ХСН. Результаты. Полученные результаты демонстрируют положительное влияние применения МСС у пациентов с ХСН и ФП на обратное ремоделирование ЛЖ, функциональный класс ХСН, а также уровни про-натрийуретического N-концевого пептида (NT-pro-BNP) независимо от формы ФП. Заключение. Применение МСС может являться перспективным методом лечения в дополнение к оптимальной медикаментозной терапии у пациентов с ХСН и ФП.

Aim: to study the effect of cardiac contractility modulation (CCM) in patients with chronic heart failure (CHF) and atrial fibrillation (AF). Materials and methods. In a group of 100 patients with CHF and AF, the following studies were performed before implantation of the CCM and after 6 months of follow-up: 12-channel ECG, transthoracic Echocardiography, 6-minute walk test, determination of the level of pro-natriuretic N-terminal peptide (NT-proBNP), and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ). All patients received long-term optimal medication therapy for CHF before surgery. Results. The results show a positive effect of the use of MCC in patients with CHF and AF on reverse LV remodeling, functional class of CHF, and levels of NT-pro-BNP regardless of the form of AF. Conclusion. The use of MCC may be a promising treatment method in addition to optimal medication therapy in patients with CHF and AF.

сердечная недостаточностьфибрилляция предсердиймодуляция сердечной сократимостифракция выброса левого желудочкакачество жизниheart failureatrial fibrillationmodulation of heart contractilityleft ventricular ejection fractionquality of lifeReferencesThihalolipavan S, Morin DP. Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis. 2015; 58 (2): 126-135. doi: 10.1016/j.pcad.2015.07.004.Thihalolipavan S, Morin DP. Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis. 2015; 58 (2): 126-135. doi: 10.1016/j.pcad.2015.07.004.Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002; 13 (4): 399-405. doi: 10.1046/j.1540-8167.2002.00399.x.Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002; 13 (4): 399-405. doi: 10.1046/j.1540-8167.2002.00399.x.Ponikowski P, Voors AA, Anker SD, Bueno H, Cle -land JG, Coats AJ et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129-2200. doi: 10.1093/eurheartj/ehw128.Ponikowski P, Voors AA, Anker SD, Bueno H, Cle -land JG, Coats AJ et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129-2200. doi: 10.1093/eurheartj/ehw128.Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS et al. ESC-HFA HF Long-Term Registry Investigatorset al; Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39 (48): 4277-4284. doi: 10.1093/eurheartj/ehy626.Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS et al. ESC-HFA HF Long-Term Registry Investigatorset al; Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39 (48): 4277-4284. doi: 10.1093/eurheartj/ehy626.Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24: 442-463. doi: 10.1016/s0195-668x(02)00823-0.Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24: 442-463. doi: 10.1016/s0195-668x(02)00823-0.Wijesurendra RS, Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc Res. 2015; 105: 238247. doi: 10.1093/cvr/cvv001.Wijesurendra RS, Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc Res. 2015; 105: 238247. doi: 10.1093/cvr/cvv001.Ziff OJ, Carter PR, McGowan J, Uppal H, Chandran S, Russell S et al. The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: insights from the United Kingdom ACALM registry. Int J Cardiol. 2018; 252: 117121. doi: 10.1016/j.ij-card.2017.06.033.Ziff OJ, Carter PR, McGowan J, Uppal H, Chandran S, Russell S et al. The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: insights from the United Kingdom ACALM registry. Int J Cardiol. 2018; 252: 117121. doi: 10.1016/j.ij-card.2017.06.033.Lardizabal JA, Deedwania PC. Atrial fibrillation in heart failure. Med Clin North Am. 2012; 96: 987-1000. doi: 10.1016/j.mcna.2012.07.007.Lardizabal JA, Deedwania PC. Atrial fibrillation in heart failure. Med Clin North Am. 2012; 96: 987-1000. doi: 10.1016/j.mcna.2012.07.007.Roy D, Talajic M, Nattel S, Wyse D G, Dorian P, Lee KL et al. Atrial Fibrillation and Congestive Heart Failure. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358: 2667-2677. doi: 10.1056/NEJMoa0708789.Roy D, Talajic M, Nattel S, Wyse D G, Dorian P, Lee KL et al. Atrial Fibrillation and Congestive Heart Failure. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358: 2667-2677. doi: 10.1056/NEJMoa0708789.Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008; 359: 17781785. doi: 10.1056/NEJMoa0708234.Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008; 359: 17781785. doi: 10.1056/NEJMoa0708234.Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al. CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417427. doi: 10.1056/NEJ-Moa1707855.Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al. CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417427. doi: 10.1056/NEJ-Moa1707855.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2020 Aug; 00: 1-126. doi: 10.1093/eurheartj/ehaa612.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2020 Aug; 00: 1-126. doi: 10.1093/eurheartj/ehaa612.Huang W, Su L, Wu S. Pacing treatment of atrial fibrillation patients with heart failure: His bundle pacing combined with atrioventricular node ablation. Card Electrophysiol Clin. 2018; 10: 519535. doi: 10.1016/j.ccep.2018.05.016.Huang W, Su L, Wu S. Pacing treatment of atrial fibrillation patients with heart failure: His bundle pacing combined with atrioventricular node ablation. Card Electrophysiol Clin. 2018; 10: 519535. doi: 10.1016/j.ccep.2018.05.016.Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E et al. APAF-CRT Investigators. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018; 39: 3999-4008. doi: 10.1093/eur-heartj/ehy555.Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E et al. APAF-CRT Investigators. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018; 39: 3999-4008. doi: 10.1093/eur-heartj/ehy555.Abi-Samra F, Gutterman D. Cardiac contractility modulation: a novel approach for the treatment of heart failure. Heart Fail Rev. 2016; 21 (6): 645-660. doi: 10.1007/s10741-016-9571-6.Abi-Samra F, Gutterman D. Cardiac contractility modulation: a novel approach for the treatment of heart failure. Heart Fail Rev. 2016; 21 (6): 645-660. doi: 10.1007/s10741-016-9571-6.Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21 (10): 1169-1186. doi: 10.1002/ejhf.1531.Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21 (10): 1169-1186. doi: 10.1002/ejhf.1531.Tint D, Florea R, Micu S. New Generation Cardiac Contractility Modulation Device-Filling the Gap in Heart Failure Treatment. J Clin Med. 2019 Apr 29; 8 (5): 588. doi: 10.3390/jcm8050588. doi: 10.3390/jcm8050588.Tint D, Florea R, Micu S. New Generation Cardiac Contractility Modulation Device-Filling the Gap in Heart Failure Treatment. J Clin Med. 2019 Apr 29; 8 (5): 588. doi: 10.3390/jcm8050588. doi: 10.3390/jcm8050588.Ревишвили АШ, Артюхина ЕА, Амирасланов АЮ, Васковский ВА, Яшков МВ, Купцов ВВ и др. Первый опыт лечения пациентов с хронической сердечной недостаточностью методом имплантации устройств, модулирующих сокращения сердца. Вестник аритмологии. 2017; (90): 12-18.Revishvili ASh, Artyukhina EA, Amiraslanov AYu, Vaskovsky VA, Yashkov MV, Kuptsov VV et al. The first experience of treatment of patients with chronic heart failure using cardiac contractility modulation device. Journal of arrhythmology. 2017; (90): 12-18.Ускач ТМ, Сафиуллина АА, Сапельников ОВ, Амана-това ВА, Николаева ОА, Гришин ИР и др. Модуляция сердечной сократимости у пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий. Терапевтический архив. 2020; 92 (9): 8-14. doi: 10.26442/00403660.2020.09.000598.Uskach TM, Safiullina AA, Sapel'nikov OV, Amanatova VA, Nikolaeva OA, Grishin IR et al. Modulation of cardiac contractility in patients with chronic heart failure and atrial fibrillation. Therapeutic Archive. 2020; 92 (9): 8-14. doi: 10.26442/00403660.2020.09.000598.Mando R, Goel A, Habash F, Saad M, Ayoub K, Vallurupalli S et al. Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hindawi Cardiovascular Therapeutics. 2019; 2019, Article ID 9769724: 10. doi: 10.1155/2019/9769724.Mando R, Goel A, Habash F, Saad M, Ayoub K, Vallurupalli S et al. Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hindawi Cardiovascular Therapeutics. 2019; 2019, Article ID 9769724: 10. doi: 10.1155/2019/9769724.Anker SD, Borggrefe M, Neuser H, Ohlow M-A, Roger S, Goette A et al. Cardiac Contractility Modulation Improves Long-Term Survival and Hospitalizations in Heart Failure With Reduced Ejection Fraction. Eur J Heart Fail. 2019 Sep; 21 (9): 1103-1113. doi: 10.1002/ejhf.1374.Anker SD, Borggrefe M, Neuser H, Ohlow M-A, Roger S, Goette A et al. Cardiac Contractility Modulation Improves Long-Term Survival and Hospitalizations in Heart Failure With Reduced Ejection Fraction. Eur J Heart Fail. 2019 Sep; 21 (9): 1103-1113. doi: 10.1002/ejhf.1374.

The authors declare that there are no conflicts of interest present.